Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity

Marzia Lotrionte, Giuseppe Biondi-Zoccai, Antonio Abbate, Gaetano Lanzetta, Fabrizio D'Ascenzo, Vincenzo Malavasi, Mariangela Peruzzi, Giacomo Frati, Giovanni Palazzoni

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

The management of individual patients requiring anthracyclines remains challenging because uncertainty persists on predictors of cardiotoxicity. We aimed to perform a systematic review and meta-analysis on incidence and predictors of anthracycline chemotherapy in patients with cancer. Databases were searched for pertinent studies. Meta-analytic pooling with random-effects methods was performed for incidence estimates, while relying on descriptive statistics for prevalence and strength of association of predictors. From 16,054 retrieved citations, 18 studies reporting on 49,017 patients with cancer were included, with 22,815 treated with anthracyclines. After a median follow-up of 9 years, clinically overt cardiotoxicity occurred in 6% (95% confidence interval 3% to 9%), whereas subclinical cardiotoxicity developed in 18% (95% confidence interval 12% to 24%). Appraisal of independent risk factors of cardiotoxicity showed that cumulative anthracycline dose was most consistently reported as an accurate and robust predictor of cardiotoxicity, with an acceptable prognostic role also for chest radiotherapy, African-American ethnicity, very young or very old age, diabetes, hypertension, very high or very low body weight, or severe co-morbidities. In conclusion, despite ongoing refinements in chemotherapy regimens, anthracyclines still pose a significant risk of cardiotoxicity, especially in those requiring a high cumulative dose or chest radiotherapy.

Original languageEnglish
Pages (from-to)1980-1984
Number of pages5
JournalThe American Journal of Cardiology
Volume112
Issue number12
DOIs
Publication statusPublished - Dec 15 2013

Fingerprint

Anthracyclines
Meta-Analysis
Incidence
Radiotherapy
Thorax
Confidence Intervals
Drug Therapy
African Americans
Uncertainty
Cardiotoxicity
Neoplasms
Body Weight
Databases
Hypertension
Morbidity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Lotrionte, M., Biondi-Zoccai, G., Abbate, A., Lanzetta, G., D'Ascenzo, F., Malavasi, V., ... Palazzoni, G. (2013). Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. The American Journal of Cardiology, 112(12), 1980-1984. https://doi.org/10.1016/j.amjcard.2013.08.026

Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. / Lotrionte, Marzia; Biondi-Zoccai, Giuseppe; Abbate, Antonio; Lanzetta, Gaetano; D'Ascenzo, Fabrizio; Malavasi, Vincenzo; Peruzzi, Mariangela; Frati, Giacomo; Palazzoni, Giovanni.

In: The American Journal of Cardiology, Vol. 112, No. 12, 15.12.2013, p. 1980-1984.

Research output: Contribution to journalArticle

Lotrionte, M, Biondi-Zoccai, G, Abbate, A, Lanzetta, G, D'Ascenzo, F, Malavasi, V, Peruzzi, M, Frati, G & Palazzoni, G 2013, 'Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity', The American Journal of Cardiology, vol. 112, no. 12, pp. 1980-1984. https://doi.org/10.1016/j.amjcard.2013.08.026
Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. The American Journal of Cardiology. 2013 Dec 15;112(12):1980-1984. https://doi.org/10.1016/j.amjcard.2013.08.026
Lotrionte, Marzia ; Biondi-Zoccai, Giuseppe ; Abbate, Antonio ; Lanzetta, Gaetano ; D'Ascenzo, Fabrizio ; Malavasi, Vincenzo ; Peruzzi, Mariangela ; Frati, Giacomo ; Palazzoni, Giovanni. / Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. In: The American Journal of Cardiology. 2013 ; Vol. 112, No. 12. pp. 1980-1984.
@article{0025a0210af8450aa235186fea201731,
title = "Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity",
abstract = "The management of individual patients requiring anthracyclines remains challenging because uncertainty persists on predictors of cardiotoxicity. We aimed to perform a systematic review and meta-analysis on incidence and predictors of anthracycline chemotherapy in patients with cancer. Databases were searched for pertinent studies. Meta-analytic pooling with random-effects methods was performed for incidence estimates, while relying on descriptive statistics for prevalence and strength of association of predictors. From 16,054 retrieved citations, 18 studies reporting on 49,017 patients with cancer were included, with 22,815 treated with anthracyclines. After a median follow-up of 9 years, clinically overt cardiotoxicity occurred in 6{\%} (95{\%} confidence interval 3{\%} to 9{\%}), whereas subclinical cardiotoxicity developed in 18{\%} (95{\%} confidence interval 12{\%} to 24{\%}). Appraisal of independent risk factors of cardiotoxicity showed that cumulative anthracycline dose was most consistently reported as an accurate and robust predictor of cardiotoxicity, with an acceptable prognostic role also for chest radiotherapy, African-American ethnicity, very young or very old age, diabetes, hypertension, very high or very low body weight, or severe co-morbidities. In conclusion, despite ongoing refinements in chemotherapy regimens, anthracyclines still pose a significant risk of cardiotoxicity, especially in those requiring a high cumulative dose or chest radiotherapy.",
author = "Marzia Lotrionte and Giuseppe Biondi-Zoccai and Antonio Abbate and Gaetano Lanzetta and Fabrizio D'Ascenzo and Vincenzo Malavasi and Mariangela Peruzzi and Giacomo Frati and Giovanni Palazzoni",
year = "2013",
month = "12",
day = "15",
doi = "10.1016/j.amjcard.2013.08.026",
language = "English",
volume = "112",
pages = "1980--1984",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity

AU - Lotrionte, Marzia

AU - Biondi-Zoccai, Giuseppe

AU - Abbate, Antonio

AU - Lanzetta, Gaetano

AU - D'Ascenzo, Fabrizio

AU - Malavasi, Vincenzo

AU - Peruzzi, Mariangela

AU - Frati, Giacomo

AU - Palazzoni, Giovanni

PY - 2013/12/15

Y1 - 2013/12/15

N2 - The management of individual patients requiring anthracyclines remains challenging because uncertainty persists on predictors of cardiotoxicity. We aimed to perform a systematic review and meta-analysis on incidence and predictors of anthracycline chemotherapy in patients with cancer. Databases were searched for pertinent studies. Meta-analytic pooling with random-effects methods was performed for incidence estimates, while relying on descriptive statistics for prevalence and strength of association of predictors. From 16,054 retrieved citations, 18 studies reporting on 49,017 patients with cancer were included, with 22,815 treated with anthracyclines. After a median follow-up of 9 years, clinically overt cardiotoxicity occurred in 6% (95% confidence interval 3% to 9%), whereas subclinical cardiotoxicity developed in 18% (95% confidence interval 12% to 24%). Appraisal of independent risk factors of cardiotoxicity showed that cumulative anthracycline dose was most consistently reported as an accurate and robust predictor of cardiotoxicity, with an acceptable prognostic role also for chest radiotherapy, African-American ethnicity, very young or very old age, diabetes, hypertension, very high or very low body weight, or severe co-morbidities. In conclusion, despite ongoing refinements in chemotherapy regimens, anthracyclines still pose a significant risk of cardiotoxicity, especially in those requiring a high cumulative dose or chest radiotherapy.

AB - The management of individual patients requiring anthracyclines remains challenging because uncertainty persists on predictors of cardiotoxicity. We aimed to perform a systematic review and meta-analysis on incidence and predictors of anthracycline chemotherapy in patients with cancer. Databases were searched for pertinent studies. Meta-analytic pooling with random-effects methods was performed for incidence estimates, while relying on descriptive statistics for prevalence and strength of association of predictors. From 16,054 retrieved citations, 18 studies reporting on 49,017 patients with cancer were included, with 22,815 treated with anthracyclines. After a median follow-up of 9 years, clinically overt cardiotoxicity occurred in 6% (95% confidence interval 3% to 9%), whereas subclinical cardiotoxicity developed in 18% (95% confidence interval 12% to 24%). Appraisal of independent risk factors of cardiotoxicity showed that cumulative anthracycline dose was most consistently reported as an accurate and robust predictor of cardiotoxicity, with an acceptable prognostic role also for chest radiotherapy, African-American ethnicity, very young or very old age, diabetes, hypertension, very high or very low body weight, or severe co-morbidities. In conclusion, despite ongoing refinements in chemotherapy regimens, anthracyclines still pose a significant risk of cardiotoxicity, especially in those requiring a high cumulative dose or chest radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84888644213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888644213&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2013.08.026

DO - 10.1016/j.amjcard.2013.08.026

M3 - Article

VL - 112

SP - 1980

EP - 1984

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12

ER -